TRG Fast Facts

By TRG Advisors on April 17, 2025

Weekly data-driven insights on the markets and economy

Consumer spending exceeded expectations in March, with retail sales rising 1.4% on the month, surpassing the 1.2% Dow Jones estimate and the 0.2% increase in February. Excluding autos, sales were up 0.5%, driven by buyers anticipating President Trump’s tariffs, while motor vehicle and parts dealers saw a 5.3% surge. Despite declining sentiment and looming tariffs, spending remained strong, indicating resilience in consumer demand.[i]

Shares of Advanced Micro Devices (AMD) slid more than 5% on Wednesday after the company announced potential charges of up to $800 million for exporting its MI308 products to China and other countries. The new U.S. license requirement for certain semiconductor exports could impact AMD’s inventory and purchase commitments. Despite generating record revenue of $25.8 billion in 2024, these restrictions may slow the company’s growth.[ii]

OpenAI is exploring the creation of a social network to rival Elon Musk’s X and Meta’s Instagram, driven by the popularity of its new image-generation feature. The project is in the early stages and aims to leverage the viral success of anime-style renderings produced by OpenAI’s tool. OpenAI CEO Sam Altman highlighted the strain on the company’s servers due to high demand, prompting temporary usage limits as they work on efficiency improvements.[iii]

Caterpillar announced on Tuesday that Chief Operating Officer Joe Creed will succeed Jim Umpleby as CEO on May 1. Umpleby, who has been with the company for more than four decades and served as CEO for the last eight years, will transition to executive chairman. This leadership change comes as the company navigates the impact of President Trump’s tariffs and aims to maintain strategic continuity.[iv]

On Monday, Pfizer announced it would end development of its experimental daily weight-loss pill, danuglipron, after a trial participant experienced a liver injury potentially caused by the drug. The patient’s liver enzymes recovered rapidly after discontinuing the pill, but Pfizer decided to halt development following a comprehensive review of clinical data and regulatory input. Pfizer has other experimental obesity drugs in its pipeline in the early stages of development.[v]

On Monday, Goldman Sachs reported first-quarter earnings of $14.12 per share, surpassing the $12.35 estimate, with revenue reaching $15.06 billion, against the expected $14.81 billion. The bank’s profit rose 15% to $4.74 billion, driven by a 27% increase in equity trading revenue, which offset declines in other areas. [vi]


[i] Cox, Jeff. “Retail sales increased 1.4% in March, greater than expected.” CNBC, 16 April 2025, https://www.cnbc.com/2025/04/16/retail-sales-march-2025.html. Accessed April 16, 2025.

[ii] Capoot, Ashley. “AMD expects $800 million hit from U.S. chip restrictions on China.” CNBC, 16 April 2025, https://www.cnbc.com/2025/04/16/amd-800-million-export-us-chip-restrictions-china.html.Accessed April 16, 2025.

[iii] Field, Hayden and Rooney, Kate. “OpenAI considering its own social network to compete with Elon Musk’s X.” CNBC, 15 April 2025, https://www.cnbc.com/2025/04/15/openai-considering-own-social-network-to-compete-with-elon-musks-x.html. Accessed April 16, 2025.

[iv] “Caterpillar CEO Umpleby to step down, insider Joseph Creed named successor.” CNBC, 15 April 2025, https://www.cnbc.com/2025/04/15/caterpillar-ceo-umpleby-to-step-down-insider-joseph-creed-named-successor.html.Accessed April 16, 2025.

[v] Constantino, Annika Kim. “Pfizer scraps daily weight loss pill after liver injury in one patient.” CNBC, 14 April 2025, https://www.cnbc.com/2025/04/14/pfizer-scraps-daily-weight-loss-pill-danuglipron.html. Accessed April 16, 2025.

[vi] Son, Hugh. “Goldman Sachs tops estimates on boom in equities trading revenue.” CNBC, 14 April 2025, https://www.cnbc.com/2025/04/14/goldman-sachs-gs-earnings-q1-2025.html. Accessed April 16, 2025.


The Rand Group is a group comprised of investment professionals registered with Hightower Advisors, LLC, an SEC registered investment adviser. Some investment professionals may also be registered with Hightower Securities, LLC (member FINRA and SIPC). Advisory services are offered through Hightower Advisors, LLC. Securities are offered through Hightower Securities, LLC.

This is not an offer to buy or sell securities, nor should anything contained herein be construed as a recommendation or advice of any kind. Consult with an appropriately credentialed professional before making any financial, investment, tax or legal decision. No investment process is free of risk, and there is no guarantee that any investment process or investment opportunities will be profitable or suitable for all investors. Past performance is neither indicative nor a guarantee of future results. You cannot invest directly in an index.

These materials were created for informational purposes only; the opinions and positions stated are those of the author(s) and are not necessarily the official opinion or position of Hightower Advisors, LLC or its affiliates (“Hightower”). Any examples used are for illustrative purposes only and based on generic assumptions. All data or other information referenced is from sources believed to be reliable but not independently verified. Information provided is as of the date referenced and is subject to change without notice. Hightower assumes no liability for any action made or taken in reliance on or relating in any way to this information. Hightower makes no representations or warranties, express or implied, as to the accuracy or completeness of the information, for statements or errors or omissions, or results obtained from the use of this information. References to any person, organization, or the inclusion of external hyperlinks does not constitute endorsement (or guarantee of accuracy or safety) by Hightower of any such person, organization or linked website or the information, products or services contained therein.

Click here for definitions of and disclosures specific to commonly used terms.

Learn More About The Rand Group

Send Email

23 Corporate Plaza Drive, Suite 130
Newport Beach, CA 92660
Office: (949) 566-8326

1300 N. Holopono St., Suite 216
Kihei, HI 96753
Office: (808) 495-8000

Toll Free: (888) 546-4640
Fax: (800) 371-9547

Legal & Privacy
Web Accessibility Policy

Form Client Relationship Summary ("Form CRS") is a brief summary of the brokerage and advisor services we offer.
HTA Client Relationship Summary
HTS Client Relationship Summary

Securities offered through Hightower Securities, LLC, Member FINRA/SIPC, Hightower Advisors, LLC is a SEC registered investment adviser. brokercheck.finra.org

©2025 Hightower Advisors. All Rights Reserved.